IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income

(in CHF 1 000)

 

 

Notes

 

01.01.–30.06.2021

 

01.01.–30.06.2020

 

01.04.–30.06.2021

 

01.04.–30.06.2020

Operating income

 

 

 

 

 

 

 

 

 

 

Net gains from securities

 

4

 

379 813

 

444 506

 

144 258

 

1 191 232

Interest income

 

 

 

 

7

 

 

7

Dividend income

 

 

 

 

243

 

 

Other income

 

 

 

4

 

3

 

1

 

 

 

 

 

379 817

 

444 759

 

144 259

 

1 191 239

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

Finance expenses

 

 

 

(397)

 

(491)

 

(354)

 

(266)

Foreign exchange losses

 

 

 

(474)

 

(4)

 

(681)

 

(42)

Administrative expenses

 

7

 

(25 985)

 

(19 788)

 

(12 907)

 

(10 103)

Other expenses

 

 

 

(3 428)

 

(2 736)

 

(1 751)

 

(1 151)

 

 

 

 

(30 284)

 

(23 019)

 

(15 693)

 

(11 562)

Profit/(loss) before tax

 

8

 

349 533

 

421 740

 

128 566

 

1 179 677

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

 

(38)

 

(34)

 

(19)

 

(17)

Profit/(loss) for the period

 

 

 

349 495

 

421 706

 

128 547

 

1 179 660

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

349 495

 

421 706

 

128 547

 

1 179 660

 

 

 

 

 

 

 

 

 

 

 

Earnings/(loss) per share in CHF

 

 

 

6.31

 

7.61

 

2.32

 

21.29

Diluted earnings/(loss) per share in CHF

 

 

 

6.31

 

7.61

 

2.32

 

21.29

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer